Mdm2 and Aurora Kinase A Inhibitors Synergize to Block Melanoma Growth by Driving Apoptosis and Immune Clearance of Tumor Cells
Open accessPublished version of a preprint
The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Abstract
Therapeutics that induce cancer cell senescence can block cell proliferation and promote immune rejection. However, the risk of tumor relapse due to senescence escape may remain high due to the long lifespan of senescent cells that are not cleared. Here, we show how combining a senescence-inducing inhibitor of the mitotic kinase Aurora A (AURKA) with an MDM2 antagonist activates p53 in senescent tumors harboring wild-type 53. In the model studied, this effect is accompanied by proliferation arrest, mitochondrial depolarization, apoptosis, and immune clearance of cancer cells by antitumor leukocytes in a manner reliant upon Ccl5, Ccl1, and Cxcl9. The AURKA/MDM2 combination therapy shows adequate bioavailability and low toxicity to the host. Moreover, the prominent response of patient-derived melanoma tumors to coadministered MDM2 and AURKA inhibitors offers a sound rationale for clinical evaluation. Taken together, our work provides a preclinical proof of concept for a combination treatment that leverages both senescence and immune surveillance to therapeutic ends.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Finally, inhibition of the mitotic kinase aurora kinase a (AURKA) appears to synergize with an MDM2 antagonist in inducing senescence coupled to immunological disease control in p53-competent melanomas (Vilgelm et al., 2015).”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Vilgelm et al., 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720 · cited 10×
“Cancer Res; 75(1) January 1, 2015 Cancer Research OF2”
BackgroundMethodInfluentialSelf-citationIn Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · cited 1×
“to induce expression of endogenous p53 by inhibiting MDM2– p53 interaction (33).”
BackgroundLive or let die: the cell's response to p53
Vousden, K. H., & Lu, X. (2002) · Nature Reviews Cancer · doi:10.1038/nrc864 · Cited by 3,192 · cited 1×
“p53 activates expression of key proapoptotic mitochondrial proteins, including PUMA, NOXA, and BAX, that promote mitochondrial membrane depolarization, leading to release of apoptotic effectors (34).”
BackgroundHauschild, A., Grob, J.-J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C. U., Miller, W. H., Kaempgen, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60868-x · Cited by 2,989
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Self-citationDrug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805
A landscape of driver mutations in melanoma
Hodis, E., Watson, I. R., Kryukov, G. V., Arold, S. T., Imielinski, M., Theurillat, J.-P., Nickerson, E., Auclair, D., Li, L., Place, C., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.024 · Cited by 2,610 · cited 2×
“CDKN2A inactivation has been implicated in disabling p53 tumor-suppressor activity in melanoma, as illustrated by the mutually exclusive pattern of CDKN2A and TP53 mutations (13, 18).”
BackgroundSenescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · cited 4×
“Consistent with previous findings in hepatocellular carcinoma and sarcoma (21, 43), p53 activation failed to initiate classical caspase-driven apoptosis in melanoma.”
BackgroundResultInfluentialSurvival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156
Self-citation
Cited by
Senolytic drugs: from discovery to translation
Kirkland, J. L., & Tchkonia, T. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13141 · Cited by 1,227
Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy
Du, R., Huang, C., Liu, K., Li, X., & Dong, Z. (2021) · Molecular Cancer · doi:10.1186/s12943-020-01305-3 · Cited by 586
“One study showed that AURKA and MDM2 antagonism with MLN8237 and Nutlin-3 halted melanoma growth by inducing growth arrest and senescence, limiting the lifespans of senescent cells, and enhancing tumor immune infiltration and clearance [215].”
BackgroundChemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy
Vilgelm, A. E., & Richmond, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00333 · Cited by 379
“Using small molecules targeting cell cycle kinases, such as alisertib that inhibits mitotic kinase Aurora A, or palbociclib that inhibits CDK4/6, to induce senescence we demonstrated that the melanoma SASP includes a number of chemokines implicated in T cell trafficking (78, 158, 159).”
BackgroundSelf-citationSenolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span
Robbins, P. D., Jurk, D., Khosla, S., Kirkland, J. L., LeBrasseur, N. K., Miller, J. D., Passos, J. F., Pignolo, R. J., Tchkonia, T., & Niedernhofer, L. J. (2021) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-050120-105018 · Cited by 360
Therapy-Induced Senescence: Opportunities to Improve Anticancer Therapy
Prasanna, P. G., Citrin, D. E., Hildesheim, J., Ahmed, M. M., Venkatachalam, S., Riscuta, G., Xi, D., Zheng, G., Deursen, J. V., Goronzy, J., et al. (2021) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djab064 · Cited by 348
“Moreover, combining a CDK4/6 inhibitor or an Aurora kinase A inhibitor with an MDM2 inhibitor resulted in induction of senescence, followed by SASP-induced tumor infiltration of cytotoxic T cells and immune clearance of the senescent tumor cells (61,62).”
BackgroundSelf-citation
Metadata
- Authors
- Vilgelm, A. E., Pawlikowski, J. S., Liu, Y., Hawkins, O. E., Davis, T. A., Smith, J., Weller, K. P., Horton, L. W., McClain, C. M., Ayers, G. D., Turner, D. C., Essaka, D. C., Stewart, C. F., Sosman, J. A., Kelley, M. C., Ecsedy, J. A., Johnston, J. N., & Richmond, A.
- Affiliations
- VA Tennessee Valley Healthcare System (US)
- Vanderbilt University (US)
- Meharry Medical College (US)
- Vanderbilt University Medical Center (US)
- St. Jude Children's Research Hospital (US)
- 11Takeda Pharmaceuticals International Co., Cambridge, Massachusetts.
- Corresponding author
- Richmond, Ann
- ORCID
- Venue
- Cancer Research
- Published
- 2015-01-01
- Volume
- 75
- Issue
- 1
- Pages
- 181-193
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- PMC
- PMC4286469
- OpenAlex
- W2113591516
- Cited by
- 115
- References
- 51
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 10 · 2023: 10 · 2022: 11 · 2021: 32 · 2020: 12 · 2019: 6 · 2018: 3 · 2017: 8 · 2016: 7 · 2015: 6
- FWCI
- 3.38
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Veterans Affairs (I01BX002301, IK6 BX005225, I01 BX000196)
- Innovative Research Group Project of the National Natural Science Foundation of China
- National Institutes of Health
- National Cancer Institute (CA 116021, F32CA171895, CA-90625, R01CA116021, R01CA034590, K12CA090625, T32CA119925, P30CA068485, P30CA021765, CA116021-S1)
- National Institute of General Medical Sciences (R01GM084333)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- melanoma, MDM2 inhibitors, Aurora A kinase inhibitor, senescence, p53 activation, apoptosis, tumor surveillance, mitochondrial depolarization, chemokines, RANTES, CCL1, CXCL9, combination therapy, senescence escape
- MeSH terms
- Animals, Antineoplastic Combined Chemotherapy Protocols, Azepines, Humans, Imidazoles, Melanoma, Melanoma, Experimental, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Nude, Piperazines, Pyrimidines, Apoptosis, Protein Kinase Inhibitors, Cell Proliferation, Proto-Oncogene Proteins c-mdm2, Aurora Kinase A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mdm2 and Aurora Kinase A Inhibitors Synergize to Block Melanoma Growth by Driving Apoptosis and Immune Clearance of Tumor Cells. https://app.cochat.ai/papers/10.1158/0008-5472.can-14-2405
- The paper
- Vilgelm, A. E., Pawlikowski, J. S., Liu, Y., Hawkins, O. E., Davis, T. A., Smith, J., Weller, K. P., Horton, L. W., McClain, C. M., Ayers, G. D., Turner, D. C., Essaka, D. C., Stewart, C. F., Sosman, J. A., Kelley, M. C., Ecsedy, J. A., Johnston, J. N., & Richmond, A. (2015). Mdm2 and Aurora Kinase A Inhibitors Synergize to Block Melanoma Growth by Driving Apoptosis and Immune Clearance of Tumor Cells. Cancer Research. https://doi.org/10.1158/0008-5472.can-14-2405
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.